The primary objective is to directly compare the efficacy of acamprosate, naltrexone and placebo for relapse prevention in alcoholics.
The primary objective is to directly compare the efficacy of acamprosate, naltrexone and placebo for relapse prevention in alcoholics. The secondary objective is to establish an association between patients' motivational type and drug effects. The aim is to improve alcoholism treatment by identifying characteristics for response to specific pharmacological relapse prevention. Such items could allow for an individually adapted pharmacotherapy of alcoholism. Specifically, we will study the possible dependence of the efficacy of naltrexone and/or acamprosate on different motivational types (reward versus relief craving) and genetic profiles referring to glutamatergic and opioidergic candidate genes. Lastly, the longterm costs and cost-effectiveness of the different treatment strategies for alcoholics chosen in our study are established.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
435
mg\&d 90 days
Department of Psychiatry, University of Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Department of Psychiatry, University of Heidelberg
Heidelberg, Baden-Wurttemberg, Germany
Department of Addictive Behavior und Addiction Medicine, Central Institute of Mental Health
Mannheim, Baden-Wurttemberg, Germany
Department of Psychiatry, University of Tübingen
Tübingen, Baden-Wurttemberg, Germany
time to relapse to heavy drinking (consumption of more than 48 gram alcohol/day for females and more than 60 gram alcohol/day for males)
Time frame: 06/2008
percentage of days without heavy drinking (consumption of more than 48 gram alcohol/day for females and more than 60 gram alcohol/day for males)
Time frame: 06/2008
time to first alcohol consumption
Time frame: 06/2008
percentage of days of complete abstinence from alcohol
Time frame: 06/2008
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Department of Psychiatry, University of Regensburg
Regensburg, Bavaria, Germany